Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats
Open Access
- 1 January 2017
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 1092015
Abstract
Simvastatin is a lipid‐lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia‐induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK‐MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK‐MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF‐κB in the diabetic heart. Cardiac caspase‐3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia‐induced oxidative stress, inflammation, and apoptosis.Keywords
Funding Information
- King Saud University (RGP-1438-005)
This publication has 72 references indexed in Scilit:
- Taurine attenuates oxidative stress and alleviates cardiac failure in type I diabetic ratsCroatian Medical Journal, 2013
- Protective Effects of Simvastatin, a Lipid Lowering Agent, against Oxidative Damage in Experimental Diabetic RatsJournal of Lipids, 2011
- Diabetic Downregulation of Nrf2 Activity via ERK Contributes to Oxidative Stress–Induced Insulin Resistance in Cardiac Cells In Vitro and In VivoDiabetes, 2011
- NF-κB, Inflammation, and Metabolic DiseaseCell Metabolism, 2011
- Diabetic cardiomyopathy, causes and effectsReviews in Endocrine and Metabolic Disorders, 2010
- WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis Factor-α (TNF-α)-stimulated Cardiac Fibroblast Proliferation but Inhibits TNF-α-induced Cardiomyocyte DeathJournal of Biological Chemistry, 2009
- Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathwayLife Sciences, 2008
- TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathwaysJournal of Clinical Investigation, 2007
- Pretreatment with simvastatin reduces myocardial no‐reflow by opening mitochondrial KATP channelBritish Journal of Pharmacology, 2006
- Oxidative stress and redox signalling in cardiac hypertrophy and heart failureHeart, 2006